Oncurious

Oncurious NV is an emerging biotech company focusing on the development of the next oncology treatments #NextGenImmunoOncology #PediatricBrainCancer

[Ophthalmology Times @OphthTimes]

. @Oxurion publishes results from Phase 1 trial of THR-687 for #DME treatment; is now recruiting patients for Phase 2 clinical study https://t.co/DnoTHqWkLT

[MEDiSTRAVA, an Inizio Company @MEDiSTRAVA_]

Published papers by @Oxurion in the Journal of Pharmacokinetics and Pharmacodynamics describe desirable #clinicalstudy profiles of THR-149 and THR-687 for #retinalvascular disorders:

https://t.co/DFbY99wmgS

#lifesciences #biopharma #publishing #opthamology

[Oncurious @Oncurious]

Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal https://t.co/1y3u4Vm8g8

[Vs. Cancer @Vs_Cancer]

As we close out #BrainTumorAwarenessMonth, we hope you will join us & #GiveHopeAName by making a donation to @PBTF in honor of every child who has battled a brain tumor.
Donate today: https://t.co/vQY8ETP5bX
#CareCureThrive #BrainCancerAwareness #GoGray #BrainTumorAwareness

[Oncurious @Oncurious]

@VIBLifeSciences @CarmelietLab @vib_ccb @KU_Leuven @americanacad Congratulations Prof. Peter Carmeliet!

[Oncurious @Oncurious]

Beursblik: bemoedigende resultaten bij Oncurious 💪https://t.co/ccBXXw3wSy

[Oncurious @Oncurious]

Very excited and proud to present encouraging data from a Phase 1 Phase 1 Dose Escalation Study of #TB403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma https://t.co/BuwRISTrH9 #AACR21 #cancerresearch @Oncurious @NMTRC @VIBLifeSciences @CarmelietLab

[Oncurious @Oncurious]

Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting https://t.co/Mqcma1xVLe

[Oncurious @Oncurious]

Excited to attend and present preclinical and clinical data at the AACR 2021 Annual Meeting! thttps://bit.ly/2PGc2md #ccr8 #immunotherapy #tb403 #medulloblastoma

[Oncurious @Oncurious]

Journal of ImmunoTherapy for Cancer published research findings by @Oncurious @VIBLifeSciences highlighting efficacy and safety of targeting CCR8 for depletion of tumor-promoting ti-Tregs in combo with anti-PD-1 therapy https://t.co/ZwIQfm0Wrz #immunotherapy #cancer #CCR8 #leuven

[Oncurious @Oncurious]

We've got news from our I-O portfolio! @Oncurious @VIBLifeSciences Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program. Follow the link to our updated website: https://t.co/wcQvCcsEPa

[Oncurious @Oncurious]

Moreover, bij @Oncurious zijn we #ontrack om rond mid 2020 een eerste preklinische PoC voor te stellen We werken aan immuno-oncotherapieën van de volgende generatie voor een breed spectrum van kankertypes. @Oxurion is 85% eigenaar, @VIBLifeSciences 15% #partnersinscience

[Oncurious @Oncurious]

Congrats to the @Oxurion and @Bicycle_tx team ! 👏

[Oncurious @Oncurious]

@ONCURIOUS NV Receives $1 M Grant from VLAIO to Progress Pipeline of Next Generation Cancer Immunotherapies https://t.co/D96ofZftcz #nextlevel

[Oncurious @Oncurious]

@Oxurion: ook het @Oncurious team blijft niet bij de pakken zitten. Recrutering van 4de (laatste) cohort van patientjes in onze Ph 1/2 studie met antiPlGF voor behandeling van medulloblastoma. Over onze I/O projecten met @VIBLifeSciences hebben we het later nog wel ;-) #staytuned

[CCB_VIB_KUL @vib_ccb]

Today is #WorldCancerDay 🍀. At the CCB we focus every day on #Cancer research, raise #Awareness about it and make it a global priority to #improve early #diagnosis & #discover effective #treatments for all patients.

[Endothelial Cell News @endothelialnews]

Our featured story this week! Role of Glutamine Synthetase in Angiogenesis beyond Glutamine Synthesis @LeuvenU @harvardmed @nature @CarmelietLab https://t.co/g7CSljg4Qd

[Oncurious @Oncurious]

Congratulations @ThromboGenics ! https://t.co/zu1RcvwoYE

[Oncurious @Oncurious]

Congratulations to Prof Peter Carmeliet @vib_ccb @VIBLifeSciences ! Well deserved! https://t.co/9X6nrXUM1e

[VIB @VIBLifeSciences]

Peter Carmeliet @vib_ccb #VIB @LeuvenU is the first Belgian researcher to receive the Heineken prize for medicine for his pioneering research on blood vessel formation https://t.co/u1k7xB1EjE

[Oncurious @Oncurious]

Hij vertrok vanuit #Leuven om elke dag 76 kilometer te lopen. Aangekomen! Van harte gefeliciteerd @SwinnenJohan ! https://t.co/XGcBXL1xOV